TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare. A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year. TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.